December « 2015 « Science and Enterprise

Airway-on-Chip Model Simulates Asthma, COPD

By Alan, on December 22nd, 2015%

Small airway chip (Wyss Institute, Harvard University)

22 December 2015. A biomedical engineering lab at Harvard University developed a small chip device that acts as a model of human airways to study biological processes and test drugs for diseases such as COPD and asthma. A team from Harvard’s Wyss Institute for Biologically Inspired . . . → Read More: Airway-on-Chip Model Simulates Asthma, COPD

Biotech, Bayer Partner on Gene-Editing Treatments

By Alan, on December 21st, 2015%

(NIH.gov)

21 December 2015. CRISPR Therapeutics and the drug company Bayer AG are forming a joint venture to develop gene-editing therapies for three types of genetic diseases, and later for other human and agricultural applications. The deal calls for Bayer AG, in Leverkusen, Germany, to invest at least $300 million in the joint . . . → Read More: Biotech, Bayer Partner on Gene-Editing Treatments

Lilly Licensing Biotech’s Drug Injection Technology

By Alan, on December 21st, 2015%

(FirstResponder.gov)

21 December 2015. Eli Lilly and Company is licensing a technology from Halozyme Therapeutics that makes it possible to inject biologic drugs under the skin rather than with intravenous infusions. The deal could bring Halozyme Therapeutics, a biotechnology company in San Diego, as much as $825 million.

Halozyme develops synthetic enzymes, with . . . → Read More: Lilly Licensing Biotech’s Drug Injection Technology

Challenge Seeks Treatments to Stop Asthma Allergic Advance

By Alan, on December 18th, 2015%

(Tradimus, Wikiimedia Commons)

18 December 2015. A new challenge on InnoCentive is looking for treatment strategies to halt the progression of allergic reactions leading to development of asthma. The competition has a total purse of $20,000 and a deadline for submissions of 14 February 2016. The sponsor of the challenge, pharmaceutical company Boehringer . . . → Read More: Challenge Seeks Treatments to Stop Asthma Allergic Advance

Trial Shows Clot Prevention Drug Safe, Reversible

By Alan, on December 18th, 2015%

(PublicDomainPictures, Pixabay)

18 December 2015. An early-stage clinical trial of an experimental drug to prevent blood clots during heart surgery shows the drug prevents platelet accumulation, while still safe and temporary to prevent excess bleeding. The study by a team at Tufts University Medical Center in Boston and Sinai Hospital of Baltimore appears . . . → Read More: Trial Shows Clot Prevention Drug Safe, Reversible

Detailed Brain Activity Imaging Being Developed

By Alan, on December 17th, 2015%

(Arthur Toga, UCLA/NIH.gov)

17 December 2015. An engineering group at University of Arizona is developing a new technology that promises to provide better images of electrical activity in the brain. The project, led by Arizona biomedical engineering professor Russell Witte, is funded by a three-year, $1.15 million grant from National Institute of Neurological . . . → Read More: Detailed Brain Activity Imaging Being Developed

Galapagos Licensing Inflammation Drug in $2.1B Deal

By Alan, on December 17th, 2015%

(National Institutes of Health)

17 December 2015. A biotechnology company is licensing its small molecule drug for treating inflammatory disorders to the biopharmaceutical company Gilead Sciences in a deal valued at nearly $2.1 billion. The agreement includes Gilead Sciences taking an ownership stake in Galapagos NV, based in Mechelin, Belgium.

The deal involves . . . → Read More: Galapagos Licensing Inflammation Drug in $2.1B Deal

Synthetic Peptide Protects Neurons Damaged by Parkinson’s

By Alan, on December 16th, 2015%

(AllanAjifo, Wikimedia Commons)

16 December 2015. A study by a start-up biotechnology company and university medical center shows an engineered peptide can protect brain cells in lab mice from damage by toxins like those causing Parkinson’s disease. The findings by a team from Longevity Biotech in Philadelphia and University of Nebraska Medical Center . . . → Read More: Synthetic Peptide Protects Neurons Damaged by Parkinson’s

Nanofibers, Stem Cells Studied for Rotator Cuff Repair

By Alan, on December 16th, 2015%

Helen Lu (Columbia University)

16 December 2015. An engineering lab at Columbia University is researching a new regenerative process that better integrates human tendon and bone tissue to repair rotator cuff injuries. The team led by biomedical engineering professor Helen Lu is funded by $1.1 million grant from Congressionally Directed Medical Research Programs . . . → Read More: Nanofibers, Stem Cells Studied for Rotator Cuff Repair

Trial Underway Testing Opioid Dependency Treatments

By Alan, on December 15th, 2015%

(e-Magine Art/Flickr)

15 December 2015. A late-stage clinical trial testing weekly and monthly treatments of injected buprenorphine for opioid drug dependence began enrolling patients. The trial is testing the drug code-named CAM2038 developed by the pharmaceutical company Camurus AB in Lund, Sweden, and licensed to Braeburn Pharmaceuticals in Princeton, New Jersey that offers . . . → Read More: Trial Underway Testing Opioid Dependency Treatments

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise